Bupivacaine
- Generic Name
- Bupivacaine
- Brand Names
- Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C18H28N2O
- CAS Number
- 38396-39-3
- Unique Ingredient Identifier
- Y8335394RO
- Background
Bupivacaine is a widely used local anesthetic agent.
- Indication
As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.
...
- Associated Conditions
- Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions
- Associated Therapies
- General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co
DURECT Corporation sold its ALZET® osmotic pumps to Lafayette Instrument Co. for $17.5 million, focusing on developing larsucosterol for alcohol-associated hepatitis. The sale strengthens DURECT's cash position and extends its cash runway through mid-2025.
Uptake Of Novel Non-Opioid Drug Suzetrigine Could Benefit From No Pain Act
Suzetrigine, a non-opioid pain treatment, showed positive Phase 3 data and is expected to be approved by the FDA in January 2025. The No Pain Act, set to be implemented in 2025, aims to boost uptake of non-opioid treatments by mandating Medicare coverage for such treatments in ambulatory surgical centers and hospital outpatient departments. The Alternatives to Pain Act, introduced by Senators Tillis and Kelly, seeks to further improve access to non-opioid pain management options for seniors and disabled individuals.
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024
DURECT Corporation to present data on larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024, Nov 15-19 in San Diego, including Phase 2b trial results supporting Phase 3 trial design.
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
DURECT Corporation details Phase 3 trial design for larsucosterol in treating severe alcohol-associated hepatitis (AH), aiming for 90-day survival endpoint. The trial, planned to enroll 200 patients, follows FDA agreement under Breakthrough Therapy designation. Larsucosterol showed reduced mortality in AH patients in the AHFIRM trial, prompting the FDA to grant Fast Track and Breakthrough Therapy designations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath